BACKGROUND: The neurodevelopmental outcomes of human immunodeficiency virus type 1 (HIV-1)-infected Ugandan infants of nondrug-using mothers were studied using controlled, prospective methodology. METHOD: The sample of 436 full-term infants included 79 HIV-infected infants of HIV-1-infected mothers, 241 uninfected infants of HIV-1-infected mothers (seroreverters), and 116 uninfected infants born to HIV-negative mothers. Neurologic status, information processing ability, and motor and mental development were assessed from 6 to 24 months of age. Observations of caretaker-child interaction and home environments were made at 6 and 12 months. All evaluators were blinded to the HIV status of the child and family. RESULTS: Compared with seroreverters and uninfected infants, HIV-infected infants demonstrated greater deficits in motor development and neurologic status, and more frequent and earlier onset of motor and neurologic abnormalities. Compared with controls, HIV-infected infants had more abnormalities in mental development at 6 and 18 months and an earlier onset of abnormalities. By 12 months, 30% of HIV-infected infants demonstrated motor abnormalities and 26% cognitive abnormalities as compared with 11% and 6% among seroreverters and 5% and 6% among seronegative infants. HIV-infected infants (62%) demonstrated a higher probability of developing an abnormal neurologic examination by 12 months, compared with seroreverters (17%) or seronegative infants (15%). Information-processing abilities did not differ as a function of HIV infection. Home environments and infants' interactions with caretakers were similar across groups. CONCLUSION: We conclude that HIV infection results in more frequent and earlier abnormalities in infants' neurologic status and motor development that are not attributable to other biological and environmental risk factors. More frequent mental developmental abnormalities were evident at several ages. However, information-processing abilities, such as recognition memory, may be spared from HIV-related deficits.
BACKGROUND: The neurodevelopmental outcomes of human immunodeficiency virus type 1 (HIV-1)-infected Ugandan infants of nondrug-using mothers were studied using controlled, prospective methodology. METHOD: The sample of 436 full-term infants included 79 HIV-infectedinfants of HIV-1-infected mothers, 241 uninfected infants of HIV-1-infected mothers (seroreverters), and 116 uninfected infants born to HIV-negative mothers. Neurologic status, information processing ability, and motor and mental development were assessed from 6 to 24 months of age. Observations of caretaker-child interaction and home environments were made at 6 and 12 months. All evaluators were blinded to the HIV status of the child and family. RESULTS: Compared with seroreverters and uninfected infants, HIV-infectedinfants demonstrated greater deficits in motor development and neurologic status, and more frequent and earlier onset of motor and neurologic abnormalities. Compared with controls, HIV-infectedinfants had more abnormalities in mental development at 6 and 18 months and an earlier onset of abnormalities. By 12 months, 30% of HIV-infectedinfants demonstrated motor abnormalities and 26% cognitive abnormalities as compared with 11% and 6% among seroreverters and 5% and 6% among seronegative infants. HIV-infectedinfants (62%) demonstrated a higher probability of developing an abnormal neurologic examination by 12 months, compared with seroreverters (17%) or seronegative infants (15%). Information-processing abilities did not differ as a function of HIV infection. Home environments and infants' interactions with caretakers were similar across groups. CONCLUSION: We conclude that HIV infection results in more frequent and earlier abnormalities in infants' neurologic status and motor development that are not attributable to other biological and environmental risk factors. More frequent mental developmental abnormalities were evident at several ages. However, information-processing abilities, such as recognition memory, may be spared from HIV-related deficits.
Authors: Theodore D Ruel; Michael J Boivin; Hannah E Boal; Paul Bangirana; Edwin Charlebois; Diane V Havlir; Philip J Rosenthal; Grant Dorsey; Jane Achan; Carolyne Akello; Moses R Kamya; Joseph K Wong Journal: Clin Infect Dis Date: 2012-02-04 Impact factor: 9.079
Authors: Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Joseph Kagaayi; Godfrey Kigozi; David Serwadda; Avy Violari; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Heena Brahmbhatt; Michael Boivin; Victor Ssempijja; Godfrey Kigozi; Joseph Kagaayi; David Serwadda; Ronald H Gray Journal: J Acquir Immune Defic Syndr Date: 2014-11-01 Impact factor: 3.731
Authors: Ronak Chhaya; Jonathan Weiss; Victoria Seffren; Alla Sikorskii; Paula M Winke; Julius C Ojuka; Michael J Boivin Journal: Child Neuropsychol Date: 2017-05-22 Impact factor: 2.500
Authors: Sumona Chaudhury; Gloria K Mayondi; Paige L Williams; Jean Leidner; Roger Shapiro; Modiegi Diseko; Gbolahan Ajibola; Penny Holding; Vicki Tepper; Joseph Makhema; Chipo Petlo; George R Seage; Shahin Lockman; Betsy Kammerer Journal: AIDS Date: 2018-06-01 Impact factor: 4.177
Authors: Christine M McDonald; Karim P Manji; Roland Kupka; David C Bellinger; Donna Spiegelman; Rodrick Kisenge; Gernard Msamanga; Wafaie W Fawzi; Christopher P Duggan Journal: J Nutr Date: 2012-12-19 Impact factor: 4.798
Authors: Megan S McHenry; Carole I McAteer; Eren Oyungu; Brenna C McDonald; Chris B Bosma; Philani B Mpofu; Andrew R Deathe; Rachel C Vreeman Journal: Pediatrics Date: 2018-02 Impact factor: 7.124